Effects of alirocumab on types of myocardial infarction : Insights from the ODYSSEY OUTCOMES trial
-
White, Harvey D. (Auckland City Hospital)
;
Gabriel Steg, P. (Royal Brompton Hospital (Londres)) ;
Szarek, Michael (SUNY Downstate Medical Center School of Public Health) ;
Bhatt, Deepak L (Harvard Medical School) ;
Bittner, Vera A. (University of Alabama at Birmingham) ;
Diaz, Rafael (Instituto Cardiovascular de Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Erglis, Andrejs (University of Latvia) ;
Goodman, Shaun G. (University of Toronto) ;
Hanotin, Corinne (Sanofi) ;
Harrington, Robert A. (Department of Medicine) ;
Wouter Jukema, J. (Leiden University Medical Center) ;
Lopes, Renato D. (Duke Clinical Research Institute) ;
Mahaffey, Kenneth W. (Stanford University School of Medicine) ;
Moryusef, Angele (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals) ;
Roe, Matthew T. (Duke Clinical Research Institute) ;
Sritara, Piyamitr (Mahidol University) ;
Tricoci, Pierluigi (CSL Behring) ;
Zeiher, Andreas Michael (Goethe University) ;
Schwartz, Gregory G. (University of Colorado School of Medicine) ;
Cequier Fillat, Angel R. (Hospital Universitari de Bellvitge) ;
García-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
